Willow Biosciences Inc. Stock Toronto S.E.

Equities

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. 5-day change 1st Jan Change
- PTS -.--% Intraday chart for Willow Biosciences Inc. -.--% -.--%

Financials

Sales 2022 821K 600K 0 Sales 2023 1.17M 856K 0 Capitalization 12.42M 9.08M 0
Net income 2022 -14M -10.23M - Net income 2023 -13M -9.5M - EV / Sales 2022 -0.95 x
Net cash position 2022 15.01M 10.97M 0 Net cash position 2023 1.63M 1.19M 0 EV / Sales 2023 9.21 x
P/E ratio 2022
-0.96 x
P/E ratio 2023
-0.95 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 73.41%
More Fundamentals * Assessed data
Dynamic Chart
Willow Biosciences Provides Corporate Update and Signs New Partnered Program MT
Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients MT
Willow Biosciences Brief: Expanding into the high growth biopesticide sector with addition of new partnered program MT
Willow Biosciences Brief: Announces its first patent being issued; Anticipates filing another five patents in 2024 primarily related to its steroid production platform MT
Willow Biosciences Brief: Anticipates revenue of over $1.0 million in Q2, and over $3.5 million for 2024 on existing programs MT
Willow Biosciences Brief: Providing Corporate Update and Signs New Partnered Program MT
Willow Biosciences to Raise Up to $3 Million Via Brokered Private Placement; Shares Jumped 24% on Friday MT
Willow Biosciences Brief: Announcing Brokered Private Placement Offering To Raise Up To $3 Million MT
Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding CI
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs CI
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 19-04-11
Director of Finance/CFO - 19-04-11
Chief Tech/Sci/R&D Officer - 19-03-31
Members of the board TitleAgeSince
Chairman 63 23-02-20
Director/Board Member 63 19-04-11
Director/Board Member 51 19-04-11
More insiders
Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.
Calendar
More about the company